Company
Amazentis
We pioneered the science of Urolithin A.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B2C
- Headquarters
- Lausanne, Switzerland
- Founded
- 2007
- Customers
- Our proprietary Mitopure technology reaches consumers through category-leading partners and our own vertical brands.
Claim, correct or request removal
Record updated 18 September 2026
About
For over 18 years, Amazentis has been dedicated to one question: how do we age, and can we slow it down? That dedication led us to discover the potential of a remarkable molecule, Urolithin A, and to develop Mitopure, its proprietary, highly pure form. We are a Swiss longevity-biotech pioneer, turning rigorous aging research into clinically validated cellular nutrition.
Funding snapshot
- Latest round
- Undisclosed2024
Funding rounds
- Series D
- 2024
Products
- Other
- Mitopure
Loading relationship preview